ReSync Bio, a San Francisco, CA-based scientific software provider accelerating preclinical R&D, raised an undisclosed amount in funding.
Backers included Caffeinated Capital, Atria Ventures and angel investors including Ramsey Homsany, co-founder of Octant Bio.
The company intends to use the funds to make key hires and commercialize their platform, which is now available for use by companies and academics.
Led by CEO and Founder Mihir Trivedi, ReSync Bio is a scientific software company that makes tools to help biopharma companies accelerate their drug discovery operations. Its SaaS product serves as a single source for preclinical data, helping customers coordinate their programs across labs and CROs and bring drugs to the clinic more efficiently.
The platform automates coordination between drug discovery teams and their labs – whether they be in-house or external CROs. The software includes controlled permissioning that lets companies control data access and promote collaboration while protecting IP.
FinSMEs
25/09/2024